| PENMENVY |
125819 |
001 |
351(a) |
Meningococcal Groups A, B, C, W and Y Vaccine |
Injection |
Intramuscular |
25UG/0.5ML |
Single-Dose Vial |
2025/02/14
|
GlaxoSmithKline Biologicals |
Rx |
Licensed |
N/A |
N/A |
| VIMKUNYA |
125820 |
001 |
351(a) |
Chikungunya Vaccine, Recombinant |
Injection |
Intramuscular |
40UG/0.8ML |
Pre-Filled Syringe |
2025/02/14
|
Bavarian Nordic A/S |
Rx |
Licensed |
N/A |
N/A |
| Simlandi |
761299 |
005 |
351(k) Interchangeable |
adalimumab-ryvk |
Injection |
Subcutaneous |
80MG/0.8ML |
Autoinjector |
2025/02/14
|
Alvotech USA Inc. |
Rx |
Licensed |
adalimumab |
Humira |
| Merilog |
761325 |
001 |
351(k) Biosimilar |
insulin aspart-szjj |
Injection |
Subcutaneous |
1,000UNITS/10ML (100UNITS/ML) |
Multi-Dose Vial |
2025/02/14
|
Sanofi-Aventis U.S. LLC |
Rx |
Licensed |
insulin aspart |
Novolog |
| Merilog |
761325 |
002 |
351(k) Biosimilar |
insulin aspart-szjj |
Injection |
Subcutaneous |
300UNITS/3ML (100UNITS/ML) |
Autoinjector |
2025/02/14
|
Sanofi-Aventis U.S. LLC |
Rx |
Licensed |
insulin aspart |
Novolog |
| Ospomyv |
761392 |
001 |
351(k) Interchangeable |
denosumab-dssb |
Injection |
Subcutaneous |
60MG/ML |
Pre-Filled Syringe |
2025/02/13
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
denosumab |
Prolia |
| Xbryk |
761392 |
002 |
351(k) Interchangeable |
denosumab-dssb |
Injection |
Subcutaneous |
120MG/1.7ML (70MG/ML) |
Single-Dose Vial |
2025/02/13
|
Samsung Bioepis Co., Ltd. |
Rx |
Licensed |
denosumab |
Xgeva |
| Selarsdi |
761343 |
004 |
351(k) Interchangeable |
ustekinumab-aekn |
Injection |
Subcutaneous |
45MG/0.5ML |
Single-Dose Vial |
2025/02/12
|
Alvotech USA Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Avtozma |
761420 |
001 |
351(k) Interchangeable |
tocilizumab-anoh |
Injection |
Intravenous |
80MG/4ML (20MG/ML) |
Single-Dose Vial |
2025/01/24
|
CELLTRION, Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Avtozma |
761420 |
002 |
351(k) Interchangeable |
tocilizumab-anoh |
Injection |
Intravenous |
200MG/10ML (20MG/ML) |
Single-Dose Vial |
2025/01/24
|
CELLTRION, Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Avtozma |
761420 |
003 |
351(k) Interchangeable |
tocilizumab-anoh |
Injection |
Intravenous |
400MG/20ML (20MG/ML) |
Single-Dose Vial |
2025/01/24
|
CELLTRION, Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Avtozma |
761498 |
001 |
351(k) Interchangeable |
tocilizumab-anoh |
Injection |
Subcutaneous |
162MG/0.9ML |
Pre-Filled Syringe |
2025/01/24
|
CELLTRION, Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Avtozma |
761498 |
002 |
351(k) Biosimilar |
tocilizumab-anoh |
Injection |
Subcutaneous |
162MG/0.9ML |
Autoinjector |
2025/01/24
|
CELLTRION, Inc. |
Rx |
Licensed |
tocilizumab |
Actemra |
| Datroway |
761394 |
001 |
351(a) |
datopotamab deruxtecan-dlnk |
Injection |
Intravenous |
100MG |
Single-Dose Vial |
2025/01/17
|
Daiichi Sankyo, Inc |
Rx |
Licensed |
N/A |
N/A |
| Omvoh |
761279 |
003 |
351(a) |
mirikizumab-mrkz |
Injection |
Subcutaneous |
100MG/ML |
Autoinjector |
2025/01/15
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Omvoh |
761279 |
004 |
351(a) |
mirikizumab-mrkz |
Injection |
Subcutaneous |
200MG/2ML (100MG/ML) |
Autoinjector |
2025/01/15
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Omvoh |
761279 |
005 |
351(a) |
mirikizumab-mrkz |
Injection |
Subcutaneous |
200MG/2ML (100MG/ML) |
Pre-Filled Syringe |
2025/01/15
|
Eli Lilly and Company |
Rx |
Licensed |
N/A |
N/A |
| Opdivo Qvantig |
761381 |
001 |
351(a) |
nivolumab and hyaluronidase-nvhy |
Injection |
Subcutaneous |
600MG/5ML;10,000UNITS/5ML (120MG/2,000UNITS/ML) |
Single-Dose Vial |
2024/12/27
|
Bristol-Myers Squibb Company |
Rx |
Licensed |
N/A |
N/A |
| Wezlana |
761285 |
004 |
351(k) Biosimilar |
ustekinumab-auub |
Injection |
Subcutaneous |
45MG/0.5ML |
Autoinjector |
2024/12/26
|
Amgen Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |
| Wezlana |
761285 |
005 |
351(k) Biosimilar |
ustekinumab-auub |
Injection |
Subcutaneous |
90MG/ML |
Autoinjector |
2024/12/26
|
Amgen Inc. |
Rx |
Licensed |
ustekinumab |
Stelara |